Journal article

Added Value of Soluble Tumor Necrosis Factor-alpha Receptor 1 as a Biomarker of ESRD Risk in Patients With Type 1 Diabetes

Carol Forsblom, John Moran, Valma Harjutsalo, Tony Loughman, Johan Waden, Nina Tolonen, Lena Thorn, Markku Saraheimo, Daniel Gordin, Per-Henrik Groop, Merlin C Thomas

DIABETES CARE | AMER DIABETES ASSOC | Published : 2014

Abstract

OBJECTIVE: Recent studies have suggested that circulating levels of the tumor necrosis factor-α receptor 1 (sTNFαR1) may be a useful predictor for the risk of end-stage renal disease (ESRD) in patients with diabetes. However, its potential utility as a biomarker has not been formally quantified. RESEARCH DESIGN AND METHODS: Circulating levels of sTNFαR1 were assessed in 429 patients with type 1 diabetes and overt nephropathy from the Finnish Diabetic Nephropathy (FinnDiane) cohort study. Predictors of incident ESRD over a median of 9.4 years of follow-up were determined by Cox regression and Fine-Gray competing risk analyses. The added value of sTNFαR1 was estimated via time-dependent receiv..

View full abstract

University of Melbourne Researchers